HUP0201653A3 - The use of thiazolidine-, oxazolidinedione derivatives for the preparation of pharmaceutical compositions improving ketosis - Google Patents

The use of thiazolidine-, oxazolidinedione derivatives for the preparation of pharmaceutical compositions improving ketosis

Info

Publication number
HUP0201653A3
HUP0201653A3 HU0201653A HUP0201653A HUP0201653A3 HU P0201653 A3 HUP0201653 A3 HU P0201653A3 HU 0201653 A HU0201653 A HU 0201653A HU P0201653 A HUP0201653 A HU P0201653A HU P0201653 A3 HUP0201653 A3 HU P0201653A3
Authority
HU
Hungary
Prior art keywords
thiazolidine
preparation
pharmaceutical compositions
compositions improving
oxazolidinedione derivatives
Prior art date
Application number
HU0201653A
Other languages
English (en)
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of HUP0201653A2 publication Critical patent/HUP0201653A2/hu
Publication of HUP0201653A3 publication Critical patent/HUP0201653A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Plural Heterocyclic Compounds (AREA)
HU0201653A 1999-04-14 2000-04-13 The use of thiazolidine-, oxazolidinedione derivatives for the preparation of pharmaceutical compositions improving ketosis HUP0201653A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP10711999 1999-04-14

Publications (2)

Publication Number Publication Date
HUP0201653A2 HUP0201653A2 (en) 2002-09-28
HUP0201653A3 true HUP0201653A3 (en) 2004-12-28

Family

ID=14450976

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0201653A HUP0201653A3 (en) 1999-04-14 2000-04-13 The use of thiazolidine-, oxazolidinedione derivatives for the preparation of pharmaceutical compositions improving ketosis

Country Status (14)

Country Link
US (2) US6677363B1 (hu)
EP (1) EP1169037B1 (hu)
KR (1) KR100697582B1 (hu)
CN (1) CN1222289C (hu)
AT (1) ATE363280T1 (hu)
AU (1) AU3677900A (hu)
CA (1) CA2369694C (hu)
DE (1) DE60035032T2 (hu)
ES (1) ES2283291T3 (hu)
HU (1) HUP0201653A3 (hu)
NO (1) NO20014935L (hu)
PL (1) PL352021A1 (hu)
TW (1) TWI249401B (hu)
WO (1) WO2000061127A2 (hu)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
HUP0203837A2 (hu) * 1999-11-10 2003-03-28 Takeda Chemical Industries, Ltd. Testtömegnövekedést gátló szerek
AU2001232244A1 (en) * 2000-02-10 2001-08-20 Takeda Chemical Industries Ltd. Drug comprising combination
GB0027783D0 (en) * 2000-11-14 2000-12-27 S P A Novel use
WO2002051441A1 (fr) * 2000-12-26 2002-07-04 Sankyo Company, Limited Compositions medicinales contenant un diuretique et un agent renforçant la resistance a l'insuline
WO2002080936A1 (en) 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
DE60233655D1 (de) 2001-04-04 2009-10-22 Ortho Mcneil Janssen Pharm R und retinoid x rezeptorenmodulatoren
ATE480236T1 (de) * 2001-04-25 2010-09-15 Takeda Pharmaceutical Verwendung des abc-expressionspromotors pioglitazon zur behandlung von arteriosklerose obliterans
ATE352312T1 (de) * 2001-12-29 2007-02-15 Novo Nordisk As Kombinierte verwendung einer glp-1-verbindung und eines aldose reduktase inhibitors
EP1688148A1 (en) * 2002-12-03 2006-08-09 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones
EP1569682A2 (en) * 2002-12-03 2005-09-07 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones
US7435741B2 (en) * 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
BR112015024186B1 (pt) * 2013-03-19 2023-05-09 University Of South Florida Composições e métodos para produção de cetose de elevação e manutenção
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US10245242B1 (en) 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10245243B1 (en) 2017-12-19 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US10596130B2 (en) 2017-12-19 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US10596129B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
US10596131B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CN109562105A (zh) * 2016-08-17 2019-04-02 企业支持有限责任公司 预防或治疗听力损失的方法
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
WO2019154893A1 (en) * 2018-02-08 2019-08-15 Strekin Ag Oral extended release pharmaceutical compositions for preventing or treating hearing loss
US11241401B2 (en) 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
US10512615B1 (en) 2018-08-27 2019-12-24 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US10980772B2 (en) 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
KR102180524B1 (ko) * 2018-11-16 2020-11-18 순천대학교 산학협력단 반추동물의 산독증 예방용 완충제 조성물
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US5965589A (en) * 1994-08-10 1999-10-12 Takeda Chemical Industries, Ltd. Thiazolidinedione derivatives, their production and use
TW403748B (en) * 1994-11-02 2000-09-01 Takeda Chemical Industries Ltd An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
JPH09323930A (ja) 1996-04-04 1997-12-16 Takeda Chem Ind Ltd 悪液質の予防・治療剤
GB9712866D0 (en) 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
PL195136B1 (pl) 1997-06-18 2007-08-31 Smithkline Beecham Plc Kombinacja zawierająca 5-[4-[2-(N-metylo-N-(2-pirydylo)amino)etoksy]-benzylo] tiazolidyno-2,4-dion i jej zastosowanie
DE69919156T2 (de) * 1998-05-11 2005-11-03 Takeda Pharmaceutical Co. Ltd. Oxyiminoalkansäure derivate mit hypoglykämischer und hypolipidemischer wirkung
DE69929996T2 (de) * 1998-06-30 2006-11-16 Takeda Pharmaceutical Co. Ltd. Pharmazeutisches mittel zur behandlung von diabetes
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
AU2001277056B2 (en) * 2000-07-25 2005-09-29 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes

Also Published As

Publication number Publication date
WO2000061127A2 (en) 2000-10-19
WO2000061127A3 (en) 2001-09-07
US7595333B2 (en) 2009-09-29
PL352021A1 (en) 2003-07-14
EP1169037A2 (en) 2002-01-09
TWI249401B (en) 2006-02-21
EP1169037B1 (en) 2007-05-30
US6677363B1 (en) 2004-01-13
NO20014935L (no) 2001-12-12
KR100697582B1 (ko) 2007-03-22
AU3677900A (en) 2000-11-14
ATE363280T1 (de) 2007-06-15
NO20014935D0 (no) 2001-10-10
CA2369694A1 (en) 2000-10-19
US20040106649A1 (en) 2004-06-03
KR20010108497A (ko) 2001-12-07
ES2283291T3 (es) 2007-11-01
DE60035032T2 (de) 2008-01-24
DE60035032D1 (de) 2007-07-12
CN1222289C (zh) 2005-10-12
HUP0201653A2 (en) 2002-09-28
CA2369694C (en) 2011-01-04
CN1347319A (zh) 2002-05-01

Similar Documents

Publication Publication Date Title
HUP0201653A3 (en) The use of thiazolidine-, oxazolidinedione derivatives for the preparation of pharmaceutical compositions improving ketosis
HUP0401642A3 (en) Use of staurosporine derivatives for the preparation of pharmaceutical compositions
HUP0004120A3 (en) Use of cgmp-pde5 inhibitors for the preparation of pharmaceutical compositions treating neuropathy
IL144501A0 (en) Epothilone derivatives, methods for the preparation thereof and pharmaceutical compositions containing the same
GB0028088D0 (en) Pharmaceutical compositions
GB0001662D0 (en) Pharmaceutical compositions
AU3192700A (en) Medicinal compositions
AU3556400A (en) Pharmaceutical compositions
GB9923436D0 (en) Pharmaceutical compositions
AU2005300A (en) Medicinal compositions
HUP0004071A3 (en) Pharmaceutical compositions comprising prostaglandin derivatives
AU2177001A (en) Use of indirubine derivatives for making medicines
AU4328800A (en) Pharmaceutical formulation
AU4304400A (en) Novel pharmaceutical compositions comprising 2-isoxazole-8-aminotetralin derivatives
AU4364400A (en) Azaindole derivatives for the treatment of depression
GB9904163D0 (en) Pharmaceutical compositions
AU6460400A (en) Pharmaceutical compositions
GB9911017D0 (en) Pharmaceutical compositions
AU1732401A (en) Medicinal compositions for oral use
AU6460200A (en) Pharmaceutical compositions
IL149534A0 (en) Preparation of 3-substituted-4-arylquinolin-2-one derivatives
GB2363605B (en) Process for the preparation of alpha-aminoketone derivatives
HUP9901969A3 (en) Use of n-mercaptoalkanoyl-cysteine derivatives for the preparation of pharmaceutical compositions traiting ischemia
HUP0003159A3 (en) The use of n-monosubstituted-3-oxo-4-aza-5alpha-androst-1-en-17betha-carboxamides for the preparation of pharmaceutical compositions
HUP0200311A3 (en) Use of aroyl- or arylalkanoylpyridazines for preparation of pharmaceutical compositions